Premium
Management of autoimmune diseases after haematopoietic stem cell transplantation
Author(s) -
Holbro Andreas,
Abinun Mario,
Daikeler Thomas
Publication year - 2012
Publication title -
british journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.907
H-Index - 186
eISSN - 1365-2141
pISSN - 0007-1048
DOI - 10.1111/j.1365-2141.2012.09070.x
Subject(s) - immunology , medicine , transplantation , disease , autoimmunity , autoimmune disease , haematopoiesis , stem cell , hematopoietic stem cell transplantation , graft versus host disease , antibody , biology , pathology , genetics
Summary Autologous and allogeneic haematopoietic stem cell transplantation ( HSCT ) is an option for the treatment of malignant and non‐malignant diseases, including the severe autoimmune diseases. Intriguingly, the ‘new’ autoimmunity developing after transplantation is a constantly recognized phenomenon, which has to be differentiated from original disease relapse, toxicity, infection and graft‐ versus ‐host disease. The reported autoimmune diseases occurring in this setting are mainly antibody‐associated and organ‐specific, with scarce evidence in support for specific treatment options. This review focuses on current concepts on the pathogenesis, the available data on incidence, risk factors, manifestations and treatment of post‐ HSCT autoimmune diseases.